First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
出版年份 2023 全文链接
标题
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 11, Issue 10, Pages e007725
出版商
BMJ
发表日期
2023-11-01
DOI
10.1136/jitc-2023-007725
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Heterodimeric IL-15 (hetIL-15) reduces circulating tumor cells and metastasis formation improving chemotherapy and surgery in 4T1 mouse model of TNBC
- (2023) Vasiliki Stravokefalou et al. Frontiers in Immunology
- Tumor eradication by hetIL-15 locoregional therapy correlates with an induced intratumoral CD103intCD11b+ dendritic cell population
- (2023) Dimitris Stellas et al. Cell Reports
- Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
- (2022) Mark P. Rubinstein et al. JOURNAL OF IMMUNOLOGY
- ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential
- (2022) Wujun Chen et al. Frontiers in Immunology
- Heterodimeric IL-15 in Cancer Immunotherapy
- (2021) Cristina Bergamaschi et al. Cancers
- Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
- (2021) Kevin Conlon et al. Journal for ImmunoTherapy of Cancer
- Rationale for IL-15 superagonists in cancer immunotherapy
- (2020) Karin M. Knudson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- IL-15 in the Combination Immunotherapy of Cancer
- (2020) Thomas A. Waldmann et al. Frontiers in Immunology
- Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
- (2020) Cristina Bergamaschi et al. Journal for ImmunoTherapy of Cancer
- Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink
- (2020) John A. Hangasky et al. Frontiers in Immunology
- Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
- (2019) Karin M. Knudson et al. Journal for ImmunoTherapy of Cancer
- Harnessing NK Cells for Cancer Treatment
- (2019) Paola Minetto et al. Frontiers in Immunology
- Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques
- (2018) Cristina Bergamaschi et al. CYTOKINE
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- The potential and promise of IL-15 in immuno-oncogenic therapies
- (2017) Tanya O. Robinson et al. IMMUNOLOGY LETTERS
- Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion
- (2016) Sinnie Sin Man Ng et al. CLINICAL CANCER RESEARCH
- A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses
- (2016) Bai Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
- (2016) Mélanie Desbois et al. JOURNAL OF IMMUNOLOGY
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
- (2016) Peter S. Kim et al. Oncotarget
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells
- (2014) C Bergamaschi et al. GENE THERAPY
- Preassociation of IL-15 with IL-15R -IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
- (2014) S. Dubois et al. JOURNAL OF IMMUNOLOGY
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- Circulating IL-15 exists as heterodimeric complex with soluble IL-15R in human and mouse serum
- (2012) C. Bergamaschi et al. BLOOD
- Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
- (2010) P. Yu et al. CLINICAL CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started